Dr. Lenz on Updated Results of the CheckMate-142 Trial in mCRC

Heinz-Josef Lenz, MD, FACP
Published: Wednesday, Sep 25, 2019



Heinz-Josef Lenz, MD, FACP, professor of medicine, J. Terrance Lanni Chair in Gastrointestinal Cancer Research, and co-director, University of Southern California (USC) Center for Molecular Pathway and Drug Discovery, at the USC Norris Comprehensive Cancer Center, discusses updated results from the phase II CheckMate-142 trial in metastatic colorectal cancer (mCRC).
 
The trial examined frontline nivolumab (Opdivo) plus low-dose ipilimumab (Yervoy) in treatment-naïve patients with microsatellite instability-high/mismatch repair deficient mCRC.
At a median follow-up of 25.4 months, the objective response rate was 58%. Moreover, progression-free survival (PFS) was not yet reached with the combination.
 
These data suggest that the combination can provide patients with durable benefit,says Lenz.
SELECTED
LANGUAGE


Heinz-Josef Lenz, MD, FACP, professor of medicine, J. Terrance Lanni Chair in Gastrointestinal Cancer Research, and co-director, University of Southern California (USC) Center for Molecular Pathway and Drug Discovery, at the USC Norris Comprehensive Cancer Center, discusses updated results from the phase II CheckMate-142 trial in metastatic colorectal cancer (mCRC).
 
The trial examined frontline nivolumab (Opdivo) plus low-dose ipilimumab (Yervoy) in treatment-naïve patients with microsatellite instability-high/mismatch repair deficient mCRC.
At a median follow-up of 25.4 months, the objective response rate was 58%. Moreover, progression-free survival (PFS) was not yet reached with the combination.
 
These data suggest that the combination can provide patients with durable benefit,says Lenz.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x